KRAS and gastric cancer: Moreover, one recently described mechanism of resistance against cetuximab, that is the activating mutation of the KRAS gene, seems to have a very low prevalence in gastric cancer (Kim et al, 2003; Lee et al, 2003; Zhao et al, 2004).